New Drug Testing Program Offers Hope for Mesothelioma Patients

Share Article

Information on the effects of asbestos as well as mesothelioma research and legal options available at MesoAuthority.com

Mesothelioma Lawyers

The Sizemore Law Firm

New mesothelioma pilot drug program offers new hope for victims

The Mesothelioma Resource Center is pleased to announce a new pilot drug program that may give hope to the thousands of people affected each year by mesothelioma.

Mesothelioma is a rare form of cancer which attacks the lining of the body’s internal organs in the chest and abdomen. It is caused almost exclusively by exposure to asbestos, which was used in thousands of industrial applications during the mid-twentieth century.

There is no known cure for mesothelioma. Normally effective treatments like chemotherapy and excision surgery often don’t work as the disease spreads quickly.

Those treatments which are effective rely on early detection, which is complicated by the fact that the disease can take 20 years or more to surface after exposure. Even then, the common symptoms like chest pain, shortness of breath and restricted bowel movements often mimic those of less severe conditions.

Research of mesothelioma has often been hampered by the fact that only around 3,000 people each year are diagnosed with the disease. Many drug companies find it is not cost effective to pursue expensive research and clinical testing for a cure. Also, typical FDA testing requirements are difficult to meet due to the small number of cases available for study.

Now, a new experimental drug and a FDA pilot testing program for rare-disease drugs are offering hope that a more effective treatment will be discovered.

Japanese drug company CanBas has developed a drug that combines with traditional chemotherapy, making it more effective against mesothelioma cancer cells. The drug, called CBP501 for now, is still in the early phases of testing.

Also, the FDA recently awarded CBP501 “Orphan Drug” status. The FDA designation allows the company to use smaller testing samples to gain approval. They will also receive special tax incentives and enjoy an extended 7-year period of exclusive rights against generic drug competitors.

The Orphan Drug program is targeted at helping find prevention, treatment and cures for rare diseases, classified as those which affect less than 200,000 people each year in the United States.

The patient advocates at MesoAuthority.com are hopeful of the prospects of CBP501 and that programs such as this will spur more research into rare diseases like mesothelioma. The news may also give those currently suffering from the disease hope that a cure will soon be found.

For more information about asbestos exposure, mesothelioma symptoms, treatment and legal options including filing a mesothelioma lawsuit, visit the resource center at MesoAuthority.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Paul Sizemore
Visit website